SAINT-LAURENT, Canada, March 12 -- ART Advanced Research Technologies Inc. (ART) has partnered with DataMedix, a clinical research organization from Philadelphia, for the last clinical trial phase of its optical breast imaging device SoftScan. "Our collaboration thus far with DataMedix has proven to be very successful and we are extremely pleased with their services," said Paul Bisson, president and CEO of ART. "It is very important for us to work with a company that has successfully collaborated in a broad range of clinical research programs and regulatory approvals, and that brings highly skilled professionals to our development program. We are confident that DataMedix will help us accomplish our set objective of obtaining final approval for SoftScan) by the United States Food and Drug Administration (FDA) and Health Canada as soon as possible."